SUBCUTANEOUS LOW-DOSES OF RECOMBINANT-HUMAN-ERYTHROPOIETIN IN PREDIALYSIS PATIENTS DO NOT INTERFERE WITH THE PROGRESSION OF RENAL-FAILURE

This paper reports a study on the treatment of predialysis patients wi th recombinant human erythropoietin (r-HuEPO). The haematocrit, haemog lobin, reticulocyte and platelet values as well as creatinine and crea tinine clearance evaluated by standard and radio-isotopic methods befo re, during and after r-HuEPO treatment were determined. The slope of t he inverse creatinine versus time curves was studied too. The authors did not observe ally variation of the renal function parameters during and after study and suggest their protocol of r-HuEPO administration for predialysis patients.